TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing
    • Final enrollment: 30 participants (planned 25)
    • Site details revised
  2. Eligibility criteria expanded, about 23 words
    • Study description expanded, about 7 words
    • Publications: details revised at 1 of 1 entry
  3. 2 versions Re-verified since Feb 17, 2026, no change to tracked fieldsv14-v15
  4. Eligibility criteria expanded, about 10 words
    • Site contact updated
    • Study title expanded, about 4 words
    v13
  5. Trial status: Suspended to Recruiting
    • Site details revised
    v12
Show 10 earlier versionsHide 10 earlier versions
  1. Primary and study completion dates: May 15, 2025 to May 15, 2027v11
  2. 2 versions Re-verified since Nov 26, 2024, no change to tracked fieldsv9-v10
  3. Trial status: Recruiting to Suspended Sponsor's reason: PI Request
    • Site details revised
    v8
  4. Enrollment target: 15 to 25
    • Primary and study completion dates: May 15, 2024 to May 15, 2025
    v7
  5. 2 versions Re-verified since Sep 12, 2023, no change to tracked fieldsv5-v6
  6. Eligibility criteria shortened, about 10 wordsv4
  7. Re-verified, no change to tracked fieldsv3
  8. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 15, 2022 to Jun 6, 2022
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To measure the level of circulating tumor DNA (ctDNA) in the blood of colorectal cancer patients after 6 months of receiving TAS-102 therapy. ctDNA is genetic material from tumor cells that can be found and measured in the blood.
Trial Details
NCT Number NCT05343013
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Taiho
Conditions
(from sponsor)		 Colorectal Cancer
Related terms Colorectal Neoplasms
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov